Clinical trials
Pulmonary Hypertension (Diagnosis) clinical trials
Below are recruiting pulmonary hypertension (diagnosis) clinical trials, each written for real people, not researchers. We’re tracking 109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06038630RecruitingPhase 2
Xenon gas MRI study for lung and heart health
This study uses a special MRI scan (Xenon gas imaging) to look at how well your lungs and heart are working. It is for people with certain lung conditions, those getting blood transfusions or phlebotomy, or healthy volunteers.
Durham, North CarolinaAges 18 years+ - NCT07102823Recruiting
A registry study of lung blood vessel health in COPD
This study aims to better understand how COPD affects the blood vessels in your lungs by looking at measurements from a right heart catheterization. It may help doctors identify a specific pattern of lung and heart problems in people with COPD.
GrazAges 18 years+ - NCT05937854RecruitingPhase 2
Tadalafil to help breathing in COPD with pulmonary hypertension
This Phase 2 study tests whether tadalafil can improve breathlessness in people with COPD and pulmonary hypertension (high blood pressure in the lungs). It may help you breathe more easily if your symptoms are driven by this specific lung circulation problem.
Aurora, ColoradoAges 35–89 - NCT06475781RecruitingPhase 2
Study of mirivadelgat for pulmonary hypertension with interstitial lung disease
This study tests a new medication called mirivadelgat for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The goal is to see if it can help improve symptoms and slow the progression of the disease.
Hualien City, TaiwanAges 18–85 - NCT06715280RecruitingPhase 4
Switching from sildenafil to riociguat for CTEPH
This trial tests switching from sildenafil to a newer medicine called riociguat for people with CTEPH (a type of lung blood pressure problem) who still have symptoms after a balloon procedure. The goal is to see if the switch helps them feel better.
Hong KongAges 18 years+ - NCT05843500Recruiting
CTEPD and CTEPH registry for long-term blood-clot lung disease
This study builds a registry to learn about people with chronic blood-clot lung disease (CTEPD/CTEPH) and what symptoms and test results look like over time. It may help clinicians better understand the condition and improve future care, since your participation supports data collection rather than a new drug.
San Francisco, CaliforniaAges 18 years+ - NCT04031508Enrolling by invitationPhase 2
Omega-3 in an IV for newborns with breathing circulation problems
This trial tests whether giving an omega-3 fat medicine through an IV (along with standard care) improves breathing and blood-flow problems in newborns with congenital diaphragmatic hernia and persistent pulmonary hypertension. It may help reduce strain on the lungs and heart by targeting inflammation and blood-vessel changes.
Mexico City, Mexico CityAges 1 hour–2 weeks - NCT03980717Recruiting
Balloon procedure for severe congenital diaphragmatic hernia in pregnancy
This trial tests whether placing a tiny balloon in the fetus’s windpipe can help lungs develop and improve severe pulmonary (lung) blood pressure in babies with severe congenital diaphragmatic hernia (CDH). It may lower the chance of breathing and circulation problems after birth, but it requires a specialized procedure and close follow-up in Houston.
Houston, TexasAges 18–45 - NCT05201144RecruitingPhase 2
Test of sildenafil after diaphragm hernia surgery in newborns
This trial studies whether sildenafil (a medicine that helps relax blood vessels) can improve outcomes in babies born with a congenital diaphragmatic hernia (CDH) after they’ve had surgery. Babies are selected based on an ultrasound/echo of heart function after repair.
Salt Lake City, UtahAges Any age - NCT06129240Recruiting
Study of a new inhaled treprostinil powder for PH-ILD
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
Phoenix, ArizonaAges 18–80 - NCT06573723Recruiting
Rare disease registry at Hospital Italiano
This study collects information from patients with certain rare diseases to better understand them. If you have one of these conditions and receive care at Hospital Italiano de Buenos Aires, you may be able to join.
Buenos Aires, Buenos AiresAges Any age - NCT06832163Recruiting
Smart weaning from inhaled nitric oxide for newborns with PPHN
This trial tests a new, smart way to slowly reduce (wean) the inhaled nitric oxide gas that helps babies with a serious lung condition called PPHN. If your baby is already responding well to iNO and needs it for at least 24 hours, this study might help make the weaning process safer and more effective.
ShanghaiAges Any age - NCT06947473RecruitingPhase 1/Phase 2
CAR T-cell therapy for lupus, sclerosis, and Sjogren's
This trial tests a new type of immune cell therapy (CAR T-cells from umbilical cord blood) for people with certain autoimmune diseases that haven't responded to standard treatments. It aims to see if targeting two proteins (CD19 and BCMA) can help calm the overactive immune system.
Beijing, Beijing MunicipalityAges 6–65 - NCT07288398RecruitingPhase 3
Levosimendan for exercise limitation in PH-HFpEF
This trial tests if the drug levosimendan can help people with a specific type of pulmonary hypertension (PH-HFpEF) feel less tired and breathless during daily activities, and improve their exercise ability.
Alexander City, AlabamaAges 18–85 - NCT07333183RecruitingPhase 2
Mosliciguat plus treprostinil for lung disease with pulmonary hypertension
This trial tests a new medicine called mosliciguat combined with an inhaled treatment (treprostinil) for people who have both scarring lung disease (interstitial lung disease) and high blood pressure in the lungs. It aims to see if this combination can improve how well you feel and function.
Kissimmee, FloridaAges 18–85 - NCT07477197Recruiting
Heart Institute Biobank for Adult Congenital Heart Disease
This study collects blood and tissue samples and health information from adults with or at risk for congenital heart disease or related heart conditions. It aims to help researchers better understand these conditions and improve future treatments.
Cincinnati, OhioAges 16 years+ - NCT07285655RecruitingPhase 3
Study of L606 for lung disease with high blood pressure in the lungs
This trial tests a new treatment called L606 for people who have both a type of lung disease (ILD) and high blood pressure in the lungs (PH). The goal is to see if it is safe and helps with exercise and breathing.
Scottsdale, ArizonaAges 18–80 - NCT07143539Recruiting
Early exercise rehab after hospital stay for pulmonary embolism
This study tests if starting a supervised exercise program early after a hospital stay for a blood clot in the lungs (pulmonary embolism) helps patients recover better and feel less breathless. It is for people at higher risk of ongoing symptoms after their clot.
AarauAges 18 years+ - NCT07613099RecruitingPhase 3
Testing a new PET scan to detect lung and heart scarring
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
Bethesda, MarylandAges 18–100 - NCT07623525RecruitingPhase 1/Phase 2
DIAG723 study for hereditary hemorrhagic telangiectasia
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
Camperdown, New South WalesAges 18 years+ - NCT06649110RecruitingPhase 1/Phase 2
A study of LTP001 for healthy people and those with PAH
This study tests an investigational medicine called LTP001 for pulmonary arterial hypertension (PAH). Part A checks safety in healthy volunteers, and Part B tests if it helps people with PAH by improving blood flow in the lungs.
Scottsdale, ArizonaAges 18–100 - NCT05452889RecruitingEarly Phase 1
PET scan study in pulmonary hypertension related to scleroderma
This early study uses a PET scan (a type of imaging test) to better understand lung blood-vessel disease in people who have pulmonary hypertension related to scleroderma. It may help researchers find how imaging signals relate to disease and risk.
Pittsburgh, PennsylvaniaAges 18–75 - NCT06317805RecruitingPhase 4
Three-medicine start vs. two oral pills for new PAH
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
LinzAges 18–70 - NCT06350032RecruitingPhase 3
Testing treprostinil safety in children with PAH
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
Vienna, State of ViennaAges Up to 18 years
Hear when a new Pulmonary Hypertension (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary hypertension (diagnosis)?
- Yes. Clin2 currently lists 109 recruiting pulmonary hypertension (diagnosis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary hypertension (diagnosis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary hypertension (diagnosis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pulmonary Hypertension
- Pulmonary Arterial Hypertension
- Chronic Thromboembolic Pulmonary Hypertension
- Pulmonary Embolism (Diagnosis)
- Pulmonary Artery Hypertension
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Idiopathic Pulmonary Arterial Hypertension
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.